Market News & Trends
9/27/2011
Thermo Fisher Scientific Introduces New Imaging ATR Accessory Thermo Fisher Scientific Inc., a world leader in serving science, recently announced the launch of a new…
Ambrx & BMS Announce $24-Million Collaboration for Novel Biologics Programs
Ambrx, Inc. and Bristol-Myers Squibb Company recently announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop, and commercialize biologics…
First Application of Haselmeier's Injection Pen Launched
Haselmeier recently announced that the first application of its Axis-D pen platform has been launched. Commissioned by its client Merck Serono, a division of Merck…
Alkermes Launches Corporate Operations in Ireland
Alkermes plc recently announced the establishment of its corporate operations in Ireland, with new headquarters located in Dublin. The company, including its headquarters and operations…
9/20/2011
Unilife Develops Proprietary Portfolio of Wearable Subcutaneous Infusion Devices Unilife Corporation recently announced the development of its AutoInfusor portfolio of subcutaneous infusion systems for…
BioSante Pharmaceuticals Successfully Completes LibiGel Pharmacokinetic Study
BioSante Pharmaceuticals, Inc. recently announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study. The top-line results indicate that LibiGel increases levels of…
F-Star & Merck Serono to Collaborate on Novel Targeted Biologics
F-Star GmbH recently announced that a research, license, and commercialization agreement was signed with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for the…
KAI Pharmaceuticals Inks $13-Million Development Deal With Ono Pharmaceutical
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, recently announced the signing of an agreement with Ono Pharmaceutical Co., Ltd. for the…
NanoSmart Begins Development of New Drug Delivery Platform for Cancer
NanoSmart Pharmaceuticals, Inc., a biopharmaceutical corporation developing novel cancer pharmaceuticals, has moved into its new corporate facility located in Laguna Hills, CA. The facility provides…
Unilife Develops Proprietary Portfolio of Wearable Subcutaneous Infusion Devices
Unilife Corporation recently announced the development of its AutoInfusor portfolio of subcutaneous infusion systems for the patient self-administration of drugs in 3-, 5-, 7-, and…
Thermo Scientific Introduces Chromatography Resource Centre
Thermo Fisher Scientific Inc., a world leader in serving science, recently introduced the web-based Thermo Scientific Chromatography Resource Centre (CRC), which provides application and method…
Xcelience Expands CTS Manufacturing & Packaging
Xcelience, a leader in early drug development, has expanded clinical trial supplies manufacturing and packaging capabilities to include four new pieces of equipment and a…
9/13/2011
Evotec & Roche to Develop Compound That Could Slow AD Progression Evotec AG and Roche AG recently announced they have entered into an exclusive worldwide…
Crescendo Bioscience Secures $56 Million
Crescendo Bioscience, a molecular diagnostics company developing quantitative biomarker tests for rheumatoid arthritis (RA) and other inflammatory diseases, recently announced it has completed a $31…
Evotec & Roche to Develop Compound That Could Slow AD Progression
Evotec AG and Roche AG recently announced they have entered into an exclusive worldwide agreement for the development and commercialization of Evotec's MAO-B inhibitor in…
Foster Introduces Custom Drug Delivery Film & Rod
Foster Corporation, a PolyMedex Discovery Group company and leader in biomedical materials, recently announced it has introduced custom extruded film and rod from drug/polymer blends…
PerkinElmer to Acquire Caliper Life Sciences for $600 Million
PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, recently announced it has signed a definitive agreement…
9/6/2011
Jennerex's Virus-Based Drug Targets & Infects Tumors Jennerex, Inc. recently announced the publication of clinical data on its lead product JX-594. For the first time…
Cyclacel Announces Phase II Trial of Sapacitabine
Cyclacel Pharmaceuticals, Inc. recently announced that the first patient has been dosed in an investigator-initiated, translational, Phase II clinical study at The University of Texas…
Jennerex's Virus-Based Drug Targets & Infects Tumors
Jennerex, Inc. recently announced the publication of clinical data on its lead product JX-594. For the first time in humans, an oncolytic virus was shown…
